X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs GLENMARK PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD GLENMARK PHARMA BIOCON LTD/
GLENMARK PHARMA
 
P/E (TTM) x 72.6 14.4 504.3% View Chart
P/BV x 6.8 3.8 179.7% View Chart
Dividend Yield % 0.2 0.3 57.2%  

Financials

 BIOCON LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
GLENMARK PHARMA
Mar-17
BIOCON LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,162993 117.0%   
Low Rs483729 66.2%   
Sales per share (Unadj.) Rs194.6325.5 59.8%  
Earnings per share (Unadj.) Rs34.439.3 87.6%  
Cash flow per share (Unadj.) Rs48.348.7 99.2%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.10.2 52.4%  
Book value per share (Unadj.) Rs241.9159.2 151.9%  
Shares outstanding (eoy) m200.00282.17 70.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.22.6 159.8%   
Avg P/E ratio x23.921.9 109.0%  
P/CF ratio (eoy) x17.017.7 96.3%  
Price / Book Value ratio x3.45.4 62.8%  
Dividend payout %2.95.1 57.1%   
Avg Mkt Cap Rs m164,440242,991 67.7%   
No. of employees `0009.213.0 71.2%   
Total wages/salary Rs m7,47016,408 45.5%   
Avg. sales/employee Rs Th4,213.97,083.9 59.5%   
Avg. wages/employee Rs Th809.01,265.4 63.9%   
Avg. net profit/employee Rs Th745.2855.1 87.2%   
INCOME DATA
Net Sales Rs m38,91191,857 42.4%  
Other income Rs m1,571374 420.4%   
Total revenues Rs m40,48292,230 43.9%   
Gross profit Rs m9,79520,367 48.1%  
Depreciation Rs m2,7722,644 104.9%   
Interest Rs m2602,373 11.0%   
Profit before tax Rs m8,33415,724 53.0%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m1,6163,827 42.2%   
Profit after tax Rs m6,88111,088 62.1%  
Gross profit margin %25.222.2 113.5%  
Effective tax rate %19.424.3 79.7%   
Net profit margin %17.712.1 146.5%  
BALANCE SHEET DATA
Current assets Rs m40,47768,746 58.9%   
Current liabilities Rs m16,78327,027 62.1%   
Net working cap to sales %60.945.4 134.1%  
Current ratio x2.42.5 94.8%  
Inventory Days Days6085 70.1%  
Debtors Days Days8396 86.7%  
Net fixed assets Rs m45,07324,132 186.8%   
Share capital Rs m1,000282 354.4%   
"Free" reserves Rs m47,37744,643 106.1%   
Net worth Rs m48,37744,925 107.7%   
Long term debt Rs m21,08245,363 46.5%   
Total assets Rs m93,942117,639 79.9%  
Interest coverage x33.17.6 433.5%   
Debt to equity ratio x0.41.0 43.2%  
Sales to assets ratio x0.40.8 53.0%   
Return on assets %7.611.4 66.4%  
Return on equity %14.224.7 57.6%  
Return on capital %12.619.1 65.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,98856,152 23.1%   
Fx outflow Rs m7,8998,084 97.7%   
Net fx Rs m5,08948,068 10.6%   
CASH FLOW
From Operations Rs m6,4006,574 97.3%  
From Investments Rs m-4,985-7,124 70.0%  
From Financial Activity Rs m-1,7755,432 -32.7%  
Net Cashflow Rs m-4731,992 -23.7%  

Share Holding

Indian Promoters % 40.4 48.3 83.6%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 6.9 121.7%  
FIIs % 10.7 34.4 31.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 56,727 193.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare BIOCON LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Jan 17, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - SANOFI INDIA COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS